Magnesium sulphate for eclampsia or eclampsia prophylaxis. The outstanding information on functional uses other than nutrient supplement as well as information on commercial use of anhydrous magnesium sulfate and magnesium sulfate was requested for evaluation by the 68th jecfa meeting. At the 18month corrected age, the longterm effects of magnesium sulfate on fetuses were evaluated. Doses of magnesium sulphate used in the prophylactic treatment were similar to those used in the treatment of eclampsia. In the magnesium sulphate for prevention of eclampsia magpie trial, researchers randomized women with preeclampsia in labor to receive magnesium sulfate or placebo and assessed rates of eclampsia. Efficacy and safety of magnesium sulphate mgso4 in the treatment of eclampsia article pdf available in journal of the indian medical association 1097. Two timelines of milestones in maternal health 198520.
The median time from 35 magnesium sulfate administration to birth was reported in only two of the trials that generated the evidence 1 hour 38 minutes and 3. Preeclampsiaeclampsia is one of the most common causes of maternal and perinatal morbidity and mortality in low and middle income countries. Who recommendation on the use of magnesium sulfate for. Pdf efficacy and safety of magnesium sulphate mgso4 in. The use of magnesium sulphate for the treatment of severe pre. Alternative magnesium sulfate dosing regimens for women. Magnesium sulfate mgso 4 has been used throughout the 20th century for prevention of eclamptic seizures, 1,2 and it continues to be used extensively.
Magnesium sulphate to prevent cerebral palsy following. Prophylactic magnesium sulphate in severe preeclampsia. Magnesium sulphate anticonvulsant therapy aims to prevent and treat eclamptic seizures background magnesium sulphate mgs0 4 more than halves the risk for eclampsia, and probably reduces the risk of maternal death. Specifically, although the multicenter european magpie trial demonstrated clear benefits of magnesium sulfate for eclampsia prophylaxis in women with severe gestational hypertension, its use for those with mild hypertension remains controversial. However, since the magpie trials, there is general international consensus that magnesium sulfate is the drug of choice to treat eclampsia. Magnesium sulphate given before verypreterm birth to protect infant brain. Results showed that magnesium administration significantly decreased the percentage of patients developing postoperative atrial fibrillation. Magnesium sulfate for the treatment of eclampsia stroke. A randomized trial comparing the pharmacology of magnesium sulfate when used to treat severe preeclampsia with serial intravenous boluses versus a continuous intravenous infusion thomas easterling1, mary hebert2, hillary bracken3, emad darwish4, mohamed cherine ramadan5. Outcome and hospital resource use data were available for the trial period from the magpie trial. Do women with preeclampsia, and their babies, benefit. Magnesium sulphate and other anticonvulsants for women with pre.
Magnesium sulfate given for seizure prophylaxis 4 6 g loading dose12 g per hour maintenance dose magpie trial established 1 gmhr dose effective controversy over whether mgso4 is needed in mild preeclampsia when closely monitored treatment usually continues for 24 hours after birth. Pdf is there a benefit to continue magnesium sulphate. Metaanalysis of the trial data indicates that antenatal magnesium. A randomized controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe preeclampsia.
We did not specify a priori a dose of magnesium, because of a paucity of evidence on doseresponse mechanics, or a method of blinding, or a specific spirometric outcome. However, this trend was not found in other key studies including the magpie trial, 17, 44, 45. Magnesium sulphate more than halved the risk of eclampsia, and probably reduced the risk of. Optimizing treatment for the prevention of preeclampsia. The magpie trial is comparing magnesium sulphate with placebo for treatment of women with preeclampsia. Magnesium sulfate for prevention of eclampsia magpie the magpie trial, a large international trial to evaluate the impact of antenatal mgso 4 administration in the prevention of eclampsia, included 10,141 women with preeclampsia between july 1998 and november 2001. Magnesium sulfate is the drug of choice for prevention of seizures as part of. Increasing uptake and correct administration of magnesium sulfate for management of severe preeclampsia and eclampsia susheela m.
Objective to evaluate the association of intrapartum magnesium sulfate for fetal neuroprotection mgso4fn with the delivery room resuscitation and neonatal outcomes of preterm infants in an era of minimisation of invasive mechanical ventilation. Manual for the bayley scales of infant development. Magnesium administered prior to preterm delivery crosses over to the foetal circulation and acts via several pathways to reduce perinatal neuronal damage. However, trials comparing magnesium sulphate with alternative agents for tocolysis of preterm labour show an increase.
Magnesium sulphate neuroprotection of preterm infants. The use of magnesium sulphate for the treatment of severe. Outcome for women at 2 years magpie trial followup study collaborative. Antenatal magnesium sulfate for neuroprotective effects in. Request pdf do women with preeclampsia, and their babies, benefit from magnesium sulphate. Oct 31, 2019 if you are allergic to magnesium sulfate injection. Antenatal magnesium sulfate for fetal neuroprotection.
Between 1998 and 2001, 10 141 women were recruited to the magpie trial at 175 hospitals in 33 countries. The magpie trial magnesium sulphate mgso 4 was first introduced to control convulsions in 1925, but it was the collaborative eclampsia trial in 1995 that confirmed the efficacy of mgso 4 in the treatment of severe preeclampsia and eclampsia. Stop magnesium sulfate infusionadministration fetal assessment administer calcium gluconate 10 ml of 10% solution over 10. Generating an epub file may take a long time, please be patient. Ii rct n 10, 141 the antenatal magnesium sulphate for neuroprotection guideline development panel antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child. Effect of magnesium sulfate exposure on term neonates. Eclampsia, the occurrence of seizures superimposed on preeclampsia, is rare but associated with a far worse outcome than pre. Furthermore with a randomised controlled trial showing. There did not appear to be any substantive harmful. Intrapartum magnesium sulfate and need for intensive delivery. Magnesium treatment for neuroprotection in ischemic diseases. Jun 01, 2002 do women with preeclampsia, and their babies, benefit from magnesium sulphate. The most concerning major side effect of magnesium sulfate is respiratory depression. Alternative regimens of magnesium sulfate for treatment of.
Give magnesium sulfate 20% solution, 4 g iv over 5 minutes 2. Magnesium sulfate reproductive health supplies coalition. The panel noted that salts of sulfuric acid, such as sodium sulfate, can be irritating to the skin so cosmetic products containing magnesium sulfate should be formulated to be nonirritating. Frontiers fetal neuroprotection by magnesium sulfate. In this multicenter, placebocontrolled, randomized trial of intravenous magnesium sulfate in women at imminent risk for delivery between 24 and 31 weeks of gestation, magnesium sulfate did not sig. Intrapartum magnesium sulfate and need for intensive. Do women with preeclampsia, and their babies, benefit from magnesium sulphate. Health system barriers to access and use of magnesium sulfate. The magpie trial compared magnesium sulphate with placebo for women with preeclampsia. Increasing uptake and correct administration of magnesium. Wall street business magnate stephen chu, winner of the strathmores whos who registry honoring the most successful business tycoons in the world, says the demolisher betting system lived up exactly to its billing. Magnesium sulfate was evaluated by the committee at its 63rd meeting.
Setting neonatal intensive care units in the canadian neonatal network. Australian injectable drugs handbook, 6th edition, society of hospital pharmacists of australia 2014. One small trial 36 women compared magnesium sulfate with isosorbide, and another trial 33 women compared magnesium chloride with methyldopa. Progression from nonsevere previously referred to as mild to severe on the disease spectrum may be gradual or rapid.
Severe preeclampsia is a common cause of maternal death, leading to approximately 50,000 maternal deaths per year. Findings demonstrate that magnesium sulfate meaningfully reduces the risk of eclamptic seizures among women with preeclampsia. Magnesium sulfate is an anticonvulsant drug recommended by. The recent magpie trail demonstrated that magnesium sulphate compared to a placebo reduced the risk of fitting by half, among 10,000 women in. The panel issued a tentative safety assessment for public comment with the conclusion that magnesium sulfate is. The use of magnesium sulphate for the treatment of eclampsia. Magnesium sulfate therapy in preeclampsia and eclampsia. Magnesium sulfate is the primary medication used in the prevention and management of eclamptic seizures and exerts its effect by depressing the central nervous system. Most women with severe maternal hypertension have preeclampsia and will be given mgso 4 based on the magnesium sulfate for prevention of eclampsia magpie trial. Safe practices to decrease the inherent risk of high alert. If convulsions recur after 15 minutes, give 2 g magnesium sulfate 50% solution iv over 5 minutes. Altman d, carroli g, duley l, farrell b, moodley j, neilson j, et al. Do women with preeclampsia, and their babies, benefit from. Magnesium sulfate for the prevention of cerebral palsy.
Magnesium sulfate is the drug of choice for prevention of seizures as part of comprehensive management of the disease. Safety assessment of magnesium sulfate as used in cosmetics. Based on high quality evidence, binational clinical practice guidelines recommend the use of antenatal magnesium sulphate for women at risk of imminent, preterm birth at less than 30 weeks for the neuroprotection of their preterm infants the. Full text perception of midwives towards magnesium sulfate. The study of magnesium sulphate vs diazepam in eclampsia. Design assessment at 18 months of age for children whose mothers w. Magnesium sulfate injection, usp 50% is a sterile, nonpyrogenic, concentrated solution of magnesium sulfate heptahydrate in water for injection. The magpie trial was primarily designed to determine the maternal neurological effects of magnesium, but also reported on neonatal outcomes. Even in the magpie trial there was diversity in the use of magnesium sulphate depending on the various trial centres. Evidence supports the use of magnesium sulfate mgso4 as the first line treatment option for severe preeclampsia and eclampsia. Introduction purpose this report summarizes the activities and results from a focused intervention to strengthen the use of evidencebased practice for management of severe preeclampsia and eclampsia spee with magnesium sulphate in 22 health facilities across nepal. These conflicting results may be explained by the timing of treatment.
Globally, magnesium sulfate mgso 4 has been recognized as the drug of choice for preventing and controlling fits among women with severe preeclampsia and eclampsia, respectively. Two randomized control trials provided the scientific evidence needed to promote mgso 4 as the anticonvulsant of choice for the treatment of severe preeclampsia and eclampsia. Severe preeclampsia and eclampsia are rare but serious complications of pregnancy that threaten the lives of mothers during childbirth. The trial also called magpie trial was a randomized, placebo. The recent magpie trail demonstrated that magnesium sulphate compared to a placebo reduced the risk of fitting by half, among 10,000 women in 33 countries worldwide.
Magpie trial multicenter international trial 10,141 randomized. Follow promptly with 10 g of 50% mgso 4 solution, 5 g in each buttock via deep im injections with 1 ml of 2% lignocaine in the same syringe. The panel concluded that magnesium sulfate is safe in the present practices of use and concentration in cosmetics, when formulated to be nonirritating. Magnesium sulphate at 30 to 34 weeks gestational age. Expectant management of severe preeclampsia and preeclampsia superimposed on chronic hypertension between 24 and 34 weeks gestation. Overall, 9024 children were included in the analysis of outcome at discharge from hospital. Selective magnesium sulfate prophylaxis for the prevention. A randomized, controlled trial of magnesium sulfate for. Altman d, carroli g, duley l, farrell b, moodley j, neilson j, smith d. Women 9996 with preeclampsia from the magpie trial. Therefore, actionable findings for improving magnesium sulfate use are needed. The incidence of eclampsia in the united states has been reported to be 1 in 3,250 births. It is administered by the intravenous iv or intramuscular im routes as an electrolyte replenisher or anticonvulsant. Magnesium sulphate to prevent cerebral palsy following preterm birth 1.
A randomised trial comparing magnesium sulphate with placebo for preeclampsia. The aim of this study was to assess longterm effects for women following the use of magnesium sulphate for preeclampsia. The current status of magnesium sulfate mgso 4 for fetal neuroprotection is an analogous situation. This is not a list of all drugs or health problems that interact with magnesium sulfate injection. Various studies have confirmed the efficacy of magnesium sulfate in reducing. Capitals indicate lifethreatening, underlines indicate most frequent. Preeclampsia is a multisystem, progressive disorder characterized by the new onset of hypertension and proteinuria or hypertension and endorgan dysfunction with or without proteinuria in the last half of pregnancy. Assessment at 23 years after delivery for women recruited to the magpie trial recruitment in 19982001, isrctn 86938761, which compared magnesium sulphate with placebo for preeclampsia. Dr l duley, magpie trial office, nuffield department of medicine, level 5, john radcliffe hospital, headington, oxford ox3 9du, uk. Treatment duration ranged from 10 to 144 hours, and the total amount of magnesium administered ranged from 7 to 110 mmol. The iv regimen required six ampoules of trial treatment 58 ml, and the im regimen eight ampoules 78 ml. Analysis of prophylaxis strategies in the united states determined that universal prophylaxis with mgso 4. Therapy with both magnesium sulfate and nifedipine does not. Eclampsia is the third major cause of maternal mortality in pakistan.
Magnesium sulphate more than halved the risk of eclampsia, and probably reduced the risk of maternal death. Magnesium sulfate versus placebo or no anticonvulsant six rcts 11 444 women, including the large multicentre magpie trial 7 involving 10 141 participants, provided the evidence for this comparison. Clinical practice guideline hypertension in pregnancy. Despite the compelling evidence for the effectiveness of magnesium sulfate, concern has been expressed about its safety and potential. Who recommendation on magnesium sulfate for the prevention. Costeffectiveness of prophylactic magnesium sulphate for. Women allocated magnesium sulphate had a 58% lower risk of eclampsia 95% ci 4071 than those allocated placebo 40. In these trials, magnesium sulfate was compared with diazepam, phenytoin, or a lytic cocktail. In this multicenter, placebocontrolled, randomized trial of intravenous magnesium sulfate in women at imminent risk for delivery between 24 and 31 weeks of gestation, magnesium sulfate. If the woman had recently received a loading dose of magnesium sulphate at a referring hospital, she could be randomised and the trial treatment loading dose omitted. Background the prevalence of preterm birth is increasing. Magnesium sulphate mgso4 was first introduced to control convulsions in 1925, but it was the collaborative eclampsia trial in 1995 that confirmed the efficacy of mgso4 in the treatment of severe preeclampsia and eclampsia. Recruitment for magenta was completed in february 2018. A threeyear study called the magpie trials was launched in.
Whereas magnesium has shown neuroprotective properties in animal models of global and focal cerebral ischemia, this effect could not be reproduced in a large human stroke trial. The significance of this is unclear, although neonatal magnesium levels are known to correlate with maternal dosing of magnesium 41, 42 and exposure to magnesium sulfate is associated with nicu admission in a dose. Tell your doctor about the allergy and what signs you had. Lower doses and preoperative initiation of magnesium achieved the greatest reduction in postoperative atrial fibrillation. Thirtythree countries participating in the magnesium sulphate for prevention of eclampsia magpie trial. Strengthening the use of magnesium sulphate for management of spee 3 i.
The drug liquid format is encapsulated in hospiras ansyr singledose. Improper use of magnesium sulfate has been reported globally. However, the gdg felt that administering magnesium sulfate at any time from immediately prior to birth, up to 24 hours prior to anticipated birth is appropriate. The canadian institutes of health research provided funding for the magcp magnesium sulphate for fetal neuroprotection project, of which this analysis is a component. The neuroprotective effect of antenatal magnesium sulfate on very preterm infants has been demonstrated in goodquality randomised controlled trials and metaanalyses. Magnesium sulfate chemical and technical assessment revised. The results of the magpie trial june 1, p 18771 confirm claims that magnesium sulphate given during labour and for at least 24 h post partum will reduce the risk of seizures in women with severe preeclampsia or imminent eclampsia. Magnesium sulfate an overview sciencedirect topics. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. Balancing the scales expanding treatment for pregnant women with lifethreatening hypertensive conditions in developing countries a report on barriers. As in many other low and middleincome countries lmic. Magnesium sulfate mgso 4 is the anticonvulsant of choice for eclampsia prophylaxis and treatment.
24 1528 926 1163 1019 368 1133 975 174 1464 120 821 1161 593 347 927 636 1479 1082 1269 247 1484 35 714 906 1383 520 1057 483 562 745 775 1488 1197 319 1082 1402 1277